Overview
Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect in which the structures on the left side of the heart are critically underdeveloped. This includes the left ventricle, mitral valve, aortic valve, and ascending aorta, which are too small or malformed to support normal systemic blood circulation. As a result, the right ventricle must pump blood to both the lungs and the rest of the body. HLHS is one of the most serious forms of congenital heart disease and is uniformly fatal without intervention. Affected newborns typically appear normal at birth but rapidly develop signs of cardiovascular collapse as the ductus arteriosus closes within the first days of life. Symptoms include cyanosis (bluish skin discoloration), rapid or labored breathing, poor feeding, lethargy, weak pulses, and cool extremities. HLHS accounts for approximately 2–3% of all congenital heart defects. The condition is slightly more common in males than females. Diagnosis is often made prenatally by fetal echocardiography or shortly after birth. Initial stabilization requires prostaglandin E1 infusion to maintain ductal patency. Definitive treatment involves a series of three staged open-heart surgical procedures: the Norwood procedure (performed in the neonatal period), the Glenn or hemi-Fontan procedure (at approximately 4–6 months), and the Fontan procedure (at 2–4 years of age). These surgeries reconfigure the circulation so that the right ventricle serves as the systemic ventricle. Cardiac transplantation is an alternative in some centers. Despite significant advances in surgical outcomes, HLHS remains associated with long-term complications including heart failure, arrhythmias, neurodevelopmental delays, and the need for lifelong cardiac follow-up. Survival has improved dramatically over recent decades, with many patients now reaching adulthood.
Also known as:
Clinical phenotype terms— hover any for plain English:
Multifactorial
Caused by a mix of several genes and environmental factors
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
9 eventsMauro H. Schenone — NA
The Hospital for Sick Children — NA
Emory University — PHASE1
Longeveron Inc. — PHASE2
Timothy J Nelson, MD, PhD — PHASE1
Carelon Research — PHASE3
Timothy J Nelson, MD, PhD — PHASE2
Metcela Inc. — PHASE3
Children's Hospital Medical Center, Cincinnati
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Hypoplastic left heart syndrome.
5 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hypoplastic left heart syndrome.
Community
No community posts yet. Be the first to share your experience with Hypoplastic left heart syndrome.
Start the conversation →Latest news about Hypoplastic left heart syndrome
Disease timeline:
New recruiting trial: Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
A new clinical trial is recruiting patients for Hypoplastic left heart syndrome
New recruiting trial: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
A new clinical trial is recruiting patients for Hypoplastic left heart syndrome
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hypoplastic left heart syndrome
What is Hypoplastic left heart syndrome?
Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect in which the structures on the left side of the heart are critically underdeveloped. This includes the left ventricle, mitral valve, aortic valve, and ascending aorta, which are too small or malformed to support normal systemic blood circulation. As a result, the right ventricle must pump blood to both the lungs and the rest of the body. HLHS is one of the most serious forms of congenital heart disease and is uniformly fatal without intervention. Affected newborns typically appear normal at birth but rapidly develop sig
How is Hypoplastic left heart syndrome inherited?
Hypoplastic left heart syndrome follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hypoplastic left heart syndrome typically begin?
Typical onset of Hypoplastic left heart syndrome is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Hypoplastic left heart syndrome?
Yes — 5 recruiting clinical trials are currently listed for Hypoplastic left heart syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Hypoplastic left heart syndrome?
25 specialists and care centers treating Hypoplastic left heart syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.